Pharma BD Deal Intelligence
Qilu Pharmaceutical Group Co., Ltd. / Mabwell (Shanghai) Bioscience Co., Ltd.
2025 · Licensing/Option · Complete
Mabwell's wholly owned subsidiary T-mab granted Qilu Pharmaceutical exclusive rights on June 27, 2025 to develop, manufacture, improve, utilize and commercialize Albipagrastim alfa for Injection in Greater China. T-mab can receive up to RMB 500 million in total upfront and sales milestone payments plus royalties of up to a double-digit percentage of net sales. USD value left NULL - no disclosed FX rate.
This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2030 at the earliest for this deal, once/if it closes.
Key facts
- Announced Jun 27, 2025
- Deal type Licensing/Option
Related deals
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals
More: 2025 deals